Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic (POCUSPAH)
Primary Purpose
POCUS Assessment During Ambulatory PAH Clinic
Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
POC-US
Sponsored by
About this trial
This is an interventional diagnostic trial for POCUS Assessment During Ambulatory PAH Clinic
Eligibility Criteria
Inclusion Criteria:
- All patients with PAH defined by the Updated clinical classification of pulmonary hypertension criteria.
- Age ≥ 18
- Baseline values from right-heart catheterization results for the definite diagnosis of PH: Hemodynamic inclusion: resting mPAP > 25mmHg, PCWP < 15mmHg, and PVR > 3 Woods Units.
Exclusion Criteria:
- Inability to give informed consent.
- Clear evidence of Group 2-5 PH. We will also exclude patients with PAH on the basis of congenital heart disease, liver cirrhosis or suspected pulmonary veno-occlusive disease.
Sites / Locations
- Soroka Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
intervention group
control group.
Arm Description
The intervention group underwent clinical evaluation and a bedside-focused sonographic assessment
The control group underwent clinical evaluation without POC-US
Outcomes
Primary Outcome Measures
percentage and the rate of patients management change, represented by change in treatment or assessment of patients in the PAH clinic
Secondary Outcome Measures
Full Information
NCT ID
NCT05332847
First Posted
March 13, 2022
Last Updated
April 10, 2022
Sponsor
Soroka University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05332847
Brief Title
Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic
Acronym
POCUSPAH
Official Title
Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic Changes Patients' Management- A Randomized Controlled Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
January 14, 2018 (Actual)
Primary Completion Date
March 11, 2019 (Actual)
Study Completion Date
June 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Soroka University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Background: Changes occurring in the pulmonary vascularity imparts changes to the right heart in patients with pulmonary arterial hypertension (PAH). Importantly changes in RV function correlates with severity of disease and patient outcome. This affords and opportunity to assess patients longitudinally through point of care ultrasonography. Investigators objective was to measure the percentage and the rate of patients management change, represented by change in treatment or assessment of patients in the PAH clinic, and to compared management change rate between patients with PAH who underwent point of care ultrasonography (POCUS) assessment in addition to the routine evaluation, and a control group to which the investigators did not add a test with POCUS in addition to the routine evaluation in the clinic.
Methods: Consecutive patients from the PAH clinic in two medical centers were randomized to the POCUS assessment group and the non-POCUS group. The POCUS group received lung, heart, and vascular ultrasound assessments. All other assessments were the same between both groups. Management changes were documented during each of the patients' visits over a three-month interval.
Detailed Description
The investigators included patients if they were diagnosed with group 1 PH (PAH), as defined by the updated clinical classification of PH and provided informed consent. Patients were excluded if diagnosed with PH group 2-5, had congenital heart disease, liver cirrhosis, or suspected pulmonary venous-occlusive disease. On enrollment, randomization of the patient was done 1:1 (using ClinStat) to either the POCUS assessment group or control group. Both groups underwent the same clinical assessment according to PH clinic protocol and by the same treating pulmonologist (A.A.). Every patient was scheduled to a follow up meeting every three months as part of the usual PAH clinic routine. The study protocol was approved by each participating center's research ethics board (BRZ 0106-18, SOR0327-16).
At each clinic visit evaluations for both groups were standardized. Each visit included a history, physical and laboratory evaluation, BNP level, 6-minute walk test, and quality of life as assessed using emPHasis 10.
Prior to the decision regarding patient management, the pulmonologist at the PAH clinic knew the test results including a POCUS test done in the intervention group. A change in the patient's management in the clinic is represented by the clinician's recommendation for a change in medication, sending the patient for a lung transplant, hospitalization, or other diagnostic or therapeutic procedure documented
Patients in the intervention group underwent a bedside-focused sonographic assessment of the heart, lungs, abdomen, and IVC in every clinic visit during the period of study. The exam was conducted either at the beginning or after the regular patient assessment. The Investigators used 2-dimensional views, the parasternal long and short axis, subcostal long and IVC, apical 5, 4, 2 chamber view. As this exam was POCUS centered and not a formal cardiac study. When pathologies were identified, relevant measurements were made, and the patient was referred for a formal echo. For example, when a calcified aortic valve was detected, and aortic stenosis was suspected a continuous pulse wave Doppler for maximal velocity measurement was conducted. Standard measurements were for left ventricle wall thickness, size of ventricles and atria, IVC size and collapsibility index, RVSP when TR was identified, TAPSE, and size of pericardial effusion when found. Lung ultrasound was focused on the detection of pulmonary congestion (screening and counting B-lines on both lungs, midclavicular line and midaxillary line), pleural effusion, lung atelectasis, lung consolidations (mid and posterior axillary lines), and sliding of pleura (midclavicular line). The investigators performed Doppler for DVT only within the right clinical context. All POCUS exams were documented in a standardized form. Findings were reported in real-time to the treating pulmonologist and were documented in the follow-up notes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
POCUS Assessment During Ambulatory PAH Clinic
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
intervention group
Arm Type
Active Comparator
Arm Description
The intervention group underwent clinical evaluation and a bedside-focused sonographic assessment
Arm Title
control group.
Arm Type
No Intervention
Arm Description
The control group underwent clinical evaluation without POC-US
Intervention Type
Device
Intervention Name(s)
POC-US
Other Intervention Name(s)
clinic visit evaluations
Intervention Description
Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
Primary Outcome Measure Information:
Title
percentage and the rate of patients management change, represented by change in treatment or assessment of patients in the PAH clinic
Time Frame
9 monthes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients with PAH defined by the Updated clinical classification of pulmonary hypertension criteria.
Age ≥ 18
Baseline values from right-heart catheterization results for the definite diagnosis of PH: Hemodynamic inclusion: resting mPAP > 25mmHg, PCWP < 15mmHg, and PVR > 3 Woods Units.
Exclusion Criteria:
Inability to give informed consent.
Clear evidence of Group 2-5 PH. We will also exclude patients with PAH on the basis of congenital heart disease, liver cirrhosis or suspected pulmonary veno-occlusive disease.
Facility Information:
Facility Name
Soroka Medical Center
City
Be'er Sheva
State/Province
Negev
ZIP/Postal Code
85510
Country
Israel
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic
We'll reach out to this number within 24 hrs